Estados Unidos · Plataformas y datos · The Motley Fool

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Publicado por The Motley Fool · Estados Unidos hace 1 h

Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

También te puede interesar

The Social Security Administration wants more babies signed up for ‘Trump accounts.’ But there’s still a catch.

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred Stock (NASDAQ:STRC) Shareholders Set to Receive $0.03 Dividend

Couche-Tard makes bid for Cumberland Farms: report

Iranian lethal plots against Americans at ’advanced stages,’ Reuters reports

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Technology Drives the Future of Travel: JETOUR Continues to Expand Its "Travel+" Ecosystem

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Compartir

También te puede interesar

The Social Security Administration wants more babies signed up for ‘Trump accounts.’ But there’s still a catch.

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred Stock (NASDAQ:STRC) Shareholders Set to Receive $0.03 Dividend

Couche-Tard makes bid for Cumberland Farms: report

Iranian lethal plots against Americans at ’advanced stages,’ Reuters reports

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Technology Drives the Future of Travel: JETOUR Continues to Expand Its "Travel+" Ecosystem